A Randomized, Double-blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence - the PATHWay Study.
The PATHWay Study investigates the efficacy of pembrolizumab, an anti-PD-1 monoclonal antibody, as an adjuvant therapy in patients with high-risk head and neck squamous cell carcinoma (HNSCC). Given the increasing incidence of HNSCC and the limited treatment options for high-risk patients, successful outcomes could position pembrolizumab as a standard of care in this setting, enhancing its market potential. The competitive landscape includes other immunotherapies and targeted agents, necessitating ongoing diligence to assess emerging data and competitor strategies.
Indication: Head and Neck Cancer
Modality: small molecule
Target: PD-1 receptor (programmed cell death protein 1)
Sponsor: University of Chicago
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Aug 04, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: PD-1 receptor (programmed cell death protein 1)
View original source fields
Condition raw: Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck
Condition normalized: Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck
Modality raw: small molecule
Modality normalized: small molecule
Target raw: PD-1 receptor (programmed cell death protein 1)
Target normalized: PD-1 receptor (programmed cell death protein 1)